Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial

Optimum formulation of Biological-E’s protein subunit CORBEVAX™ vaccine was selected in phase-1 and -2 studies and found to be safe and immunogenic in healthy adult population. This is a phase-3 prospective, single-blinded, randomized, active controlled study conducted at 18 sites across India in 18...

Descripción completa

Detalles Bibliográficos
Autores principales: Thuluva, Subhash, Paradkar, Vikram, Gunneri, SubbaReddy, Yerroju, Vijay, Mogulla, Rammohan, Suneetha, Pothakamuri Venkata, Turaga, Kishore, Kyasani, Mahesh, Manoharan, Senthil Kumar, Adabala, Srikanth, Sri Javvadi, Aditya, Medigeshi, Guruprasad, Singh, Janmejay, Shaman, Heena, Binayke, Akshay, Zaheer, Aymaan, Awasthi, Amit, Singh, Chandramani, Rao A, Venkateshwar, Basu, Indranil, Kumar, Khobragade Akash Ashok, Pandey, Anil Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Coronavirus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294721/
https://www.ncbi.nlm.nih.gov/pubmed/37113012
http://dx.doi.org/10.1080/21645515.2023.2203632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294721/
https://www.ncbi.nlm.nih.gov/pubmed/37113012
http://dx.doi.org/10.1080/21645515.2023.2203632

Ejemplares similares